Loading
Breast Cancer Treatment Studies / HER2/EGFR in Cancer Research / Advanced Breast Cancer Therapies · Journal article
Journal of Clinical Oncology · September 9, 2026
A consensus or society position rather than new primary data.
This is a clinical review proposing risk-adapted neoadjuvant therapy optimization for HER2-positive early-stage breast cancer, grounded in recent randomized trial data and two FDA-approved indications for fam-trastuzumab deruxtecan-nxki. The framework supports de-escalation strategies (omitting carboplatin, chemotherapy-free approaches) and identifies circulating tumor DNA monitoring and functional imaging as priorities for response-adapted treatment.
Journal article. Women with stage II to III HER2-positive early-stage breast cancer.
Randomized trial data indicate carboplatin can be safely omitted from neoadjuvant therapy for most patients with stage II HER2-positive early-stage breast cancer, with comparable pathological complete response rates and reduced toxicity DESTINY-Breast11 and DESTINY-Breast05 established neoadjuvant and postneoadjuvant fam-trastuzumab deruxtecan-nxki as options for high-risk disease with recent FDA approval De-escalation from docetaxel or paclitaxel, carboplatin, trastuzumab, pertuzumab to docetaxel or paclitaxel, trastuzumab, pertuzumab with weekly paclitaxel is supported by evidence
Randomized trial data indicate carboplatin can be safely omitted from neoadjuvant therapy for most patients with stage II HER2-positive early-stage breast cancer, with comparable pathological complete response rates and reduced toxicity
Clinicians should consider de-escalation strategies and risk-adapted approaches for HER2-positive early-stage breast cancer, including carboplatin omission for stage II disease and fam-trastuzumab deruxtecan-nxki for high-risk cases. Chemotherapy-free and biomarker-guided strategies warrant investigation but are not yet standard.
A narrative review synthesizing randomized trial evidence and recent regulatory approvals to propose a risk-adapted treatment framework for HER2-positive early-stage breast cancer, not reporting original trial data.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should consider de-escalation strategies and risk-adapted approaches for HER2-positive early-stage breast cancer, including carboplatin omission for stage II disease and fam-trastuzumab deruxtecan-nxki for high-risk cases. Chemotherapy-free and biomarker-guided strategies warrant investigation but are not yet standard.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Women with stage II to III human epidermal growth factor receptor 2 (HER2)–positive breast cancer commonly receive neoadjuvant therapy. Recent trials have substantially expanded treatment options for these individuals. Randomized trial data indicate that carboplatin can be safely omitted from neoadjuvant therapy for most patients with stage II HER2-positive early-stage breast cancer, with comparable pathological complete response rates and reduced toxicity. Here, we review evidence supporting de-escalation in the neoadjuvant setting from docetaxel or paclitaxel, carboplatin, trastuzumab, pertuzumab to docetaxel or paclitaxel, trastuzumab, pertuzumab with weekly paclitaxel and examine biomarker-guided strategies for further de-escalation, including chemotherapy-free approaches. DESTINY-Breast11 and DESTINY-Breast05 have established the use of neoadjuvant and postneoadjuvant fam-trastuzumab deruxtecan-nxki, respectively, as new options for high-risk disease, with both indications recently granted approval from the U S Food and Drug Administration. We propose a framework for risk-adapted treatment optimization, highlighting the potential of circulating tumor DNA monitoring and functional imaging as response-adapted strategies and identifying them as priorities for future investigation. Together, these advances support a more precise, individualized approach to caring for patients with early-stage HER2-positive breast cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.